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background:  Randomized trials show efficacy of prasugrel (pras) or ticagrelor (ticag) over clopidogrel, in acute coronary syndrome (ACS) patients 
(pts) managed with percutaneous coronary intervention (PCI). Since the selection of pts for use of pras or ticag has not been studied, a retrospective 
study was conducted to understand the real-world treatment patterns in these patients.
methods: The IMS Patient-Centric Data Warehouse was used to identify ACS-PCI pts >18 years with an in-hospital claim for pras or ticag between 
8/1/2011 and 4/30/2013. Baseline characteristics were evaluated using data from index and prior hospitalization, outpatient, and emergency 
department records with T test used for continuous and Chi-square test used for categorical variables.
results: The study included 16,098 pts treated with pras (n=13,134) or ticag (n=2,964). Compared with pras, ticag pts were older, more often 
female, had higher frequency of cardiovascular risk factors, and more frequently treated at a teaching hospital (Table). There was a higher frequency 
of unstable angina and dyslipidemia in pras pts with no difference in the type of myocardial infarction between the 2 groups.Conclusion: Observed 
data reveal differential use of pras or ticag in routine clinical practice, which may be guided by the drugs’ labeled warnings, and suggest physicians 
do not view these drugs as interchangeable. Adequate adjustments are needed when comparing clinical outcomes between ticag and pras based on 
observational data.
 
